Stonepine Capital Management LLC Has $3.92 Million Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Stonepine Capital Management LLC increased its position in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 25.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 238,222 shares of the biotechnology company's stock after purchasing an additional 48,914 shares during the quarter. Anika Therapeutics makes up 3.2% of Stonepine Capital Management LLC's holdings, making the stock its 9th largest position. Stonepine Capital Management LLC owned about 1.63% of Anika Therapeutics worth $3,921,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Anika Therapeutics during the 4th quarter worth approximately $27,000. Aquatic Capital Management LLC acquired a new stake in Anika Therapeutics in the fourth quarter valued at approximately $42,000. Tower Research Capital LLC TRC boosted its position in Anika Therapeutics by 412.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,890 shares of the biotechnology company's stock valued at $48,000 after buying an additional 2,326 shares in the last quarter. Wells Fargo & Company MN boosted its position in Anika Therapeutics by 31.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,421 shares of the biotechnology company's stock valued at $122,000 after buying an additional 1,759 shares in the last quarter. Finally, Connors Investor Services Inc. boosted its position in Anika Therapeutics by 8.0% in the fourth quarter. Connors Investor Services Inc. now owns 11,560 shares of the biotechnology company's stock valued at $190,000 after buying an additional 861 shares in the last quarter. 91.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

ANIK has been the topic of a number of research analyst reports. StockNews.com lowered shares of Anika Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 12th. Barrington Research cut their target price on shares of Anika Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research report on Monday, May 12th. Finally, B. Riley initiated coverage on shares of Anika Therapeutics in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock.

Anika Therapeutics Stock Performance

Shares of NASDAQ:ANIK traded down $0.25 during mid-day trading on Wednesday, reaching $11.71. 87,157 shares of the company's stock were exchanged, compared to its average volume of 70,539. The firm has a market capitalization of $167.93 million, a price-to-earnings ratio of -1.76 and a beta of 0.76. The business's fifty day moving average price is $14.15 and its 200-day moving average price is $15.98. Anika Therapeutics, Inc. has a twelve month low of $11.11 and a twelve month high of $29.12.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The business had revenue of $30.60 million for the quarter, compared to analyst estimates of $29.00 million. Analysts predict that Anika Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.